The Drug-Device Conundrum
This article was originally published in SRA
For drug-device combination products, the distinction between a drug and a device is not always clear cut. Cecil Nick and Peter Lassoff explain the differences and advise on how to select the correct regulatory path in the EU.
You may also be interested in...
Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even foreseen in two years.
The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.
A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.